Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017718 | 0.85 | — | — | |
| SCHEMBL733846 | 0.84 | PIK3CD (0.40) | CTHPIK3CD | |
| SCHEMBL1799094 | 0.82 | TSHR (0.40) | — | |
| SCHEMBL1072254 | 0.82 | TSHR (0.40) | — | |
| Bromide SCHEMBL11380568 | 0.79 | DNM1 (0.41) | — | |
| SCHEMBL20221379 | 0.77 | — | — | |
| SCHEMBL23477342 | 0.76 | DNM1 (0.48) | — | |
| SCHEMBL16333587 | 0.76 | DNM1 (0.48) | — | |
| SCHEMBL10436392 | 0.76 | — | — | |
| SCHEMBL12484771 | 0.76 | HTR1B (0.44) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505737-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9371264-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150166503-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. | 2015-06-18 | — | — | US | disclosed |
| US-20140256730-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166503-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | ADRB2 207/4885ADRB1 510/4885ADRB3 142/4885 |
| US-20140256730-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | ADRB2 207/4885ADRB1 510/4885ADRB3 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.